About Exscientia
Exscientia is a Healthcare company based in Oxford (United Kingdom) founded in 2012 by Chris Gibson, and was acquired by Recursion in October 2024. AI-driven drug discovery and precision medicine solutions are provided. Exscientia has raised $428.63 million across 11 funding rounds from investors including Recursion Pharmaceuticals, Evotec and BlackRock. The company has 392 employees. Exscientia has completed 1 acquisition, including Allcyte. Its chief executive, as recorded, is Chris Gibson. Its focus areas include Diversified Pharmaceuticals, Drugs, HealthTech and Life Sciences Tech. Its legal entity is EXSCIENTIA PLC.
Company details
Exscientia was founded in 2012 in Oxford, United Kingdom, and operates in the biotechnology sector. AI technologies are integrated to develop therapeutics, including the identification of drug candidates, molecule design, and preclinical experiments. Targeted therapies and personalized treatment strategies are emphasized. Research findings are published, and presentations are made in the field of precision medicine.
- Headquarters Oxford, United Kingdom
- Employees 392
- Founders Chris Gibson
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website exscientia.com
- Social LinkedIn X
- Acquired by Recursion (Oct 2024)
- Legal Name Exscientia Plc
- Date of Incorporation 29 Jun, 2021
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
- Total Equity Funding$428.63M (USD)
in 11 rounds
- Latest Funding Round$2.3M (USD), Grant
Dec 2023
- InvestorsRecursion Pharmaceuticals
& 17 more
- Employee Count392
- Investments & Acquisitions
- Acquired byRecursion
(Oct 2024)
Funding Insights of Exscientia
Exscientia has successfully raised a total of $428.63M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $2.3 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $428.63M
- Total Rounds 11
- Last Round Grant — $2.3M
- First Round $17.63M
(Sep 2017)
- Investors Count 17
Latest 10 of 11 funding rounds of Exscientia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $2.3M | Grant | – | – | |
| Oct 2021 | $160M | Post-IPO | – | – | – |
| Jul 2021 | $1.5M | Grant | – | – | |
| Apr 2021 | $225M | Series D | – | – | |
| Mar 2021 | $100M | Series C | – | BlackRock | |
| Jan 2021 | $3.26M | Grant | – | – | |
| May 2020 | $60M | Series C | – | Novo Holdings | |
| Oct 2019 | $65,607 | Grant | – | – | |
| Jan 2019 | $26M | Series B | – | Celgene, GT Healthcare Capital Partners | – |
| Jan 2019 | Series B | – | – |
18 investors in total: 18 institutional.
Investors in Exscientia
Exscientia has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Evotec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
PE firm investing in Asia | gthcap.com | Hong Kong, China | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
A venture capital firm focused on life sciences innovation. | 2017 | pivotalbiovp.cn | Hong Kong, Hong Kong SAR | |
| airstreet.com | ||||
Open Philanthropy is engaged in funding impactful global initiatives. | openphilanthropy.org | San Francisco, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Exscientia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exscientia
152 people are tracked at Exscientia (71 in leadership, 9 in board & advisors, 72 in team); the tracked headcount is 392.
| Name | Role | Group |
|---|---|---|
Chris Gibson | Co-Founder & CEO | Leadership |
Kristen Rushton | VP, Project Management & Chief of Staff | Leadership |
Matt Kinn | VP, Business Development & Corporate Initiatives | Leadership |
Najat Khan | Chief R&D Officer & Chief Commercial Officer | Leadership |
Jody Barbeau | Director, Scientific Communications | Leadership |
Fraser Cunningham | Associate Director, Medicinal Chemistry (drug Design) | Leadership |
Tim Claridge | Associate Director, NMR Analytics | Leadership |
Ashley Adams | Executive Director | Leadership |
Andrew Overton | Vice President Finance | Leadership |
Carl Brooks | Executive Director Of Chemistry | Leadership |
Denise Donnelly | Executive Business Partner | Leadership |
Teresa Anderson-Myers | Director Of Engineering | Leadership |
Charles Baker | Vice President Of Technology Development | Leadership |
Brandon Bennett | Director Global People Operatoins | Leadership |
Estelle Hamelin | Associate Director, Discovery Data Management | Leadership |
Safiye C. | Director Of Data Science | Leadership |
Andrew Wedlake | Associate Director, Data Science | Leadership |
Ian Goodfellow | Vice President - Antivirals | Leadership |
Ben Mabey | CTO | Leadership |
Chandana Haque | Executive Director of Biotech Incubator | Leadership |
132 more people are available in the full profile.
Complete people profiles for Exscientia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exscientia
Exscientia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Allcyte.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of drugs for the treatment of cancer patients | allcyte.com | Vienna, Austria | 2017 | Jun 2021 | $60.57M |
Complete acquisition details for Exscientia
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Exscientia
6 dated milestones of Exscientia across 12 years, from founding to its latest funding, stage changes and deals.
Web traffic of Exscientia
Websites that share an audience with Exscientia (exscientia.com).
Websites whose visitors overlap most with Exscientia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| labiotech.eu | 100% | 200.5K | #249,174 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Exscientia (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exscientia
Complete news archive for Exscientia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exscientia
Exscientia was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Exscientia is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Chris Gibson is the CEO of Exscientia, as recorded in our data. They have also founded this company.
Exscientia is a funded company, having raised a total of $428.63M across 11 funding rounds to date.
Exscientia has 392 employees.
Exscientia was founded in 2012 in Oxford, United Kingdom, and operates in the biotechnology sector. AI technologies are integrated to develop therapeutics, including the identification of drug candidates, molecule design, and preclinical experiments. Targeted therapies and personalized treatment strategies are emphasized. Research findings are published, and presentations are made in the field of precision medicine.
Exscientia has made 1 acquisition, including Allcyte.
Exscientia has 18 investors. Key investors include Recursion Pharmaceuticals, Evotec, BlackRock, Marshall Wace, and Gates Foundation.
Exscientia operates through Exscientia Plc.
Yes. Exscientia was acquired by Recursion in October 2024.